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Ferreira LN 1 , Ferreira PL University of Algarve, Faro, Algarve, Portugal; 2 University of Coimbra, Coimbra, Coimbra, Portugal OBJECTIVES: This study aims to describe the health related quality of life (HRQOL) of the Portuguese population and investigates sociodemographic differences. METHODS: Subjects randomly selected from the Portuguese active population (n = 2459) were assessed using the SF-36, a generic measure of HRQOL, which was converted into the preference-based SF-6D, following the Brazier algorithm. Although the sample was randomly selected, it differed slightly from the whole population. In order to correct this, post-stratified statically techniques were used to weight the initial results by gender and age, according to the population values. RESULTS: Mean global utility SF-6D scores were 0.70, and ranged from 0.73 (18-24 years) to 0.63 (55-64 years). The mean utility scores were 0.17 lower in the lower educational level than in the higher educational level (p < 0.000). Women, people living in rural areas and the elderly reported lower levels of utility scores. Nonparametric tests showed that health utility values were significantly related to employment (p < 0.000): the unskilled manual workers (0.68) reported lower utility values than the non-manual workers (0.74). For different diseases mean utility scores ranged from 0.66 (hepatitis) to 0.56 (stroke). This study was able to achieve normative data by age and gender for the SF-6D. Using QALYs as outcome measures, the difference between unskilled manual workers and non-manual workers would be equivalent to a difference of 4902€ in annual income. In this line of thinking, the difference between lower educational level and higher educational level would be equivalent to a difference of 13,889€ in annual income. CONCLUSION: We conclude that the SF-6D is an efficient tool for measuring the HRQOL in the community, so that different population groups can be compared. The preference-based utility measure used seems to adequately discriminate across different sociodemographic differences, showing that the HRQOL varies greatly between sociodemographic groups. The study sample comprised of 623 patients (43% females). Most patients (83%) were initiated on statin monotherapy of at least an equipotent dose of four (simvastatin 20 mg or equipotent statin). Overall TC goal attainment rate based on 1998 guidelines was 59% and based on new ESC guidelines was 49%. Goal attainment in patients with cardiovascular disease or diabetes changed from 69% to 49% based on old and new guidelines respectively. Our results also indicated that persistent statin use during follow-up increased goal attainment (54% versus 44% in not persistent patients using new ESC guidelines). CONCLU-SIONS: Though lipid management in recent years has become more aggressive, achievement of cholesterol goals based on the new ESC guidelines is relatively low. Therefore there is a need for highly effective lipid lowering therapies that are also well tolerated in order to achieve sufficient persistence. . CONCLUSIONS: Although in recent years aggressive statin treatment and lower baseline TC levels led to higher goal attainment 41% of the patients still did not reach goal. Therefore even more effective and well tolerated lipid lowering therapies seem to be required. To analyse the cost-effectiveness of Rosuvastatin compared to Atorvastatin in the treatment of hypercholesterolemia and prevention of ischemic heart disease (IHD) in Portugal. METHODS: A probabilistic Markov model was developed to analyse the costs and consequences of lifetime treatment with Rosuvastatin and Atorvastatin. For this purpose, results from head-to-head, randomised, double-blind trials evaluating low-density lipoprotein (LDL) changes and from a meta-analysis defining the relationship between LDL levels and fatal and non-fatal IHD events were combined. Incidence of myocardial infarction was derived from a nine-year Portuguese observational study. Death rates due to IHD and other causes were obtained from official data. Resource use in the treatment of MI was estimated by a Delphi panel of 8 Portuguese cardiologists with at least 15 years of clinical practice. Calculation of costs was done on both the societal and patients' perspectives. Eligible population was defined as untreated individuals over 35 years of age with LDL above 160 mg/dl. RESULTS: Rosuvastatin slightly increases life expectancy: 5.64 days per patient and 8832 years for the eligible population. Although the drug is more expensive, economic analysis shows that Rosuvastatin is cost saving. It saves €105 or €57 per patient on the society's or the patients' perspective, respectively. Therefore, Rosuvastatin dominates the alternative having a cost-effectiveness ratio of -€6772 and -€3682 per life year according to the society's or the patients' perspectives. In the 10,000 simulations carried out Rosuvastatin was always more efficacious than Atorvastatin, being cost saving in 56.05% of the cases. If the willingness to pay is higher than €162 (society) or €98 (patients) Rosuvastatin is cost-effective in all cases. CONCLUSION: Rosuvastatin dominates Atorvastatin in the prevention of IHD in Portugal. While treatment guidelines recommend lowering cholesterol to target levels, many remain above recommended goal (TC >4.5 mmol/dl for CHD and diabetic patients). In a clinical trial patients switched from statin monotherapy to Ezetimibe/Simvastatin (dual inhibition therapy) experienced an additional 27.5% and an 18.8% reduction in LDL-C and TC, respectively. OBJECTIVE: Assess cost-effectiveness of switching patients to Ezetimibe/Simvastatin (followed by titration on Ezetimibe/ Simvastatin) versus an atorvastatin dose titration strategy in CHD/diabetic patients who are not at goal with atorvastatin monotherapy. METHODS: Previously published decision-analytic model was used to project lifetime costs and benefits of lipid therapy. Clinical trial data were used in the model to estimate TC reductions for different treatment strategies. The effect of TC reductions on CHD event rates was estimated using Framingham equations and Finnish statistics on nonCHD-related mortality. Direct costs of CHD events in Finland [Health 2000 Survey data at the 2003 price level and also from the literature], Finnish prices for atorvastatin and Ezetimibe/Simvastatin and age specific quality-of-life weights were used to project cost/QALY. The model was run for a sample of Finnish CHD/diabetic patients (N = 25) that participated in the Finrisk 2002 study and were not at TC goal while on therapy with atorvastatin and having data on all Framingham risk factors. RESULTS: The mean age of the study sample was 60.4 (SD 7.7) years, 60% male, lipid profile on atorvastatin TC 5.4 (SD 0.9) mmol/L, HDL-C 1.3 (SD 0.3) mmol/L, triglycerides 1.8 (SD1.1) mmol/L. Switching to Ezetimibe/Simvastatin (followed by 11% titration on Ezetimibe/ Simvastatin) compared to atorvastatin titration (11%) is projected to increase undiscounted life expectancy by 0.75 years for CHD/diabetic patients with a discounted incremental cost/QALY of €9172. CONCLUSION: Switching to dual inhibition therapy, (Ezetimibe/Simvastatin) in CHD/diabetic patients not at goal on atorvastatin is projected to be a cost-effective alternative to atorvastatin titration. 
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